Ambrisentan Dosing for Pulmonary Arterial Hypertension
Start ambrisentan at 5 mg once daily, and increase to 10 mg once daily at 4-week intervals as needed and tolerated. 1
Standard Adult Dosing
The FDA-approved dosing regimen is straightforward:
- Initial dose: 5 mg orally once daily
- Titration: May increase to 10 mg once daily after 4 weeks based on clinical response and tolerability
- Administration: Do not split, crush, or chew tablets 1
This dosing schedule is supported by major guidelines 2 and has demonstrated efficacy in improving exercise capacity (6-minute walk distance improvements of 22-59 meters) and delaying clinical worsening in WHO Functional Class II-III PAH patients 1.
Renal Impairment
No dose adjustment is required for renal impairment. The FDA label does not specify renal dose adjustments, and ambrisentan's pharmacokinetic profile does not necessitate modification in kidney disease 1.
Hepatic Impairment
Exercise caution but no specific dose reduction is mandated. While the FDA label does not provide explicit hepatic dosing adjustments, ambrisentan has a notably favorable hepatic safety profile compared to other endothelin receptor antagonists. In clinical trials, aminotransferase elevations >3x upper limit of normal occurred in 0% of ambrisentan patients versus 2.3% on placebo 1. Importantly, patients who previously discontinued bosentan or sitaxsentan due to liver function abnormalities successfully transitioned to ambrisentan without recurrent hepatotoxicity 3.
Monitor liver function tests at baseline, at one month, and periodically thereafter 1.
Pregnancy - Absolute Contraindication
Ambrisentan is absolutely contraindicated in pregnancy and requires strict pregnancy prevention measures. 1
Critical pregnancy-related requirements:
- Exclude pregnancy before initiating treatment with a negative pregnancy test
- Monthly pregnancy testing required throughout treatment and for 1 month after discontinuation 1
- Mandatory contraception: Females of reproductive potential must use acceptable contraceptive methods during treatment and for one month after stopping
- REMS program enrollment: All female patients must enroll in the Ambrisentan REMS program before receiving the medication 1
Ambrisentan causes severe embryo-fetal toxicity and birth defects based on consistent animal data 1. The drug does not significantly affect oral contraceptive efficacy (norethindrone/ethinylestradiol), so standard hormonal contraception remains effective 4.
Important Clinical Considerations
Monitor hemoglobin levels at baseline, one month, and periodically thereafter. Ambrisentan causes mean hemoglobin decreases of 0.8-1.2 g/dL, with 7% of patients experiencing marked decreases (>15% from baseline). Do not initiate in patients with clinically significant anemia 1.
Peripheral edema is the most common adverse effect (17% vs 11% placebo), particularly in elderly patients ≥65 years (29% vs 4% placebo) 1.
Combination therapy is increasingly standard practice. Most contemporary PAH patients receive ambrisentan combined with phosphodiesterase-5 inhibitors (sildenafil or tadalafil), which has shown superior outcomes in improving right ventricular-pulmonary artery coupling and functional status 5.